refractory anemia with ringed sideroblasts (RARS)
Jump to navigation
Jump to search
Epidemiology
- most common acquired form of sideroblastic anemia
- 24% of cases of myelodysplastic syndrome
Pathology
- circulating blasts < 1%
- bone marrow blasts < 5%
- > 15% ringed sideroblasts in marrow
- no Auer rods
Management
- prognosis:
- 0-15% (mean 5%) transformation to acute leukemia (AML)
- survival 21-76 months (mean 49 months)
More general terms
References
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 677-78
- ↑ http://pathy.med.nagoya-u.ac.jp/atlas/img/t5/img38.jpg
- ↑ http://pathy.med.nagoya-u.ac.jp/atlas/img/t8/img33.jpg
Patient information
refractory anemia with ringed sideroblasts patient information